CJC-1295 with DAC

1. Product Overview

CJC-1295 with DAC (Drug Affinity Complex) is a highly specialized synthetic peptide designed exclusively for advanced laboratory research. It is a modified analog of Growth Hormone-Releasing Hormone (GHRH) and is utilized in studies requiring extended biological activity of GHRH, primarily due to its significantly prolonged plasma half-life.

The inclusion of the Drug Affinity Complex (DAC) is a key feature of this molecule. This modification allows the peptide to covalently bind to endogenous serum albumin upon administration. This innovative mechanism of action provides substantial protection against rapid enzymatic degradation and renal clearance, resulting in a sustained and predictable release profile compared to native GHRH or non-DAC-modified GHRH analogs.

2. Chemical and Physical Data

Attribute

Specification

Product Name

CJC-1295 with DAC (Research Grade)

Sequence

Modified GHRH(1–29) + Drug Affinity Complex

Molecular Weight

~3647.9 g/mol

Formula

[Chemical Formula Placeholder]

CAS Number

[CAS Number Placeholder]

Form

White Lyophilized Powder

Storage Condition

Store at -20°C or below.

Shelf Life

[Shelf Life Placeholder] (As supplied, unopened)

3. Mechanism of Action

CJC-1295 with DAC functions as a Growth Hormone-Releasing Hormone (GHRH) agonist. GHRH is a hypothalamic peptide that stimulates the synthesis and secretion of growth hormone (GH) from the somatotroph cells of the anterior pituitary gland.

The critical distinction of CJC-1295 with DAC is the Drug Affinity Complex (DAC) modification. This lipophilic modification facilitates the binding of the peptide to circulating serum albumin, a highly abundant plasma protein.

This covalent binding achieves two primary objectives:

1. Enzymatic Protection: The peptide, once bound to albumin, is shielded from circulating proteases and peptidases, thereby preventing degradation.
2. Reduced Renal Clearance: The combined peptide-albumin complex becomes too large to be rapidly filtered by the kidneys, which dramatically reduces the elimination rate.

The outcome is a sustained release profile, providing prolonged exposure to the GHRH agonist, which has been shown in research models to significantly extend the plasma half-life.

4. Specifications and Quality Control

The following specifications confirm the high quality and suitability of this product for laboratory research applications.

4.1. Analytical Specifications

Parameter

Specification

Analytical Method

Purity

≥ 98%

High-Performance Liquid Chromatography (HPLC)

Peptide Content

[Peptide Content Placeholder]

Amino Acid Analysis (AAA)

Water Content

[Water Content Placeholder]

Karl Fischer Titration

Mass Identification

Confirmed

Mass Spectrometry (MS)

Appearance

White Lyophilized Powder

Visual Inspection

4.2. Biological Specifications

Parameter

Specification

Reference

Half-Life

Estimated 5.8 to 8.1 days in research models.

Relevant literature and in-house data

Bioactivity

Confirmed GHRH-like activity

In vitro cell culture assay

Endotoxins

< [Endotoxin Limit Placeholder] EU/mg

Limulus Amoebocyte Lysate (LAL) Assay

5. Usage and Handling

5.1. Intended Use

FOR LABORATORY RESEARCH USE ONLY. This product is not intended for human or animal use, consumption, or therapeutic purposes. It is strictly for in vitro and in vivo scientific investigation by qualified research professionals.

5.2. Reconstitution

The lyophilized powder must be reconstituted prior to use. It is recommended to use sterile, bacteriostatic water or a suitable solvent as determined by the researcher's specific application.

Reconstitution Steps:

1. Allow the vial to reach room temperature before opening.
2. Gently inject the calculated volume of solvent (e.g., bacteriostatic water for injection) into the vial, allowing the solvent to run down the inside wall.
3. Do not shake the vial. Gently swirl the solution until the powder is fully dissolved.
4. Store the reconstituted solution as directed in Section 5.3.

A standard reconstitution protocol is available in the supplementary File Product Reconstitution Guide.

5.3. Storage and Stability

Form

Storage Temperature

Notes

Lyophilized Powder

-20°C or colder

Keep desiccated and protected from light.

Reconstituted Solution

2°C to 8°C (Refrigerator)

For short-term use; stability may vary depending on the solvent.

Long-Term Reconstituted

-20°C or colder

Aliquoting is recommended to minimize freeze-thaw cycles.

6. Safety and Regulatory Information

6.1. Hazard Identification

This material is sold exclusively for research use and is classified as a potential laboratory hazard. Appropriate safety precautions must be taken during handling.

6.2. Handling Precautions

• Wear appropriate Personal Protective Equipment (PPE), including laboratory coats, safety glasses, and gloves.
• Handle the product in a well-ventilated area or under a chemical fume hood.
• Refer to the current File Safety Data Sheet (SDS) for detailed safety information.

6.3. Regulatory Statement

The purchase and use of CJC-1295 with DAC are restricted to certified research facilities. The purchaser acknowledges that they are a qualified researcher and assumes all liability for the proper storage, handling, use, and disposal of this research material in accordance with all applicable local, state, and federal laws and regulations.

7. Related Research Resources

Resource

Description

Location

Certificate of Analysis (CoA)

Detailed lot-specific quality control data.

File CoA for Lot [Lot Number Placeholder]

Scientific Literature Review

Collection of publications related to CJC-1295 research.

File CJC-1295 DAC Research Bibliography

Technical Support Contact

For solubility or application inquiries.

Contact Person Technical Support via email

Disclaimer: All products listed are for research purposes only. CJC-1295 with DAC is not a drug, dietary supplement, or cosmetic. It has not been approved by the FDA or any other regulatory body for therapeutic use. The information provided herein is based on scientific data from general research models and is for informational purposes only.

Document Version: 1.0
Last Updated: Date
Prepared by: Person Quality Assurance Department